Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Registration Number
- NCT01947608
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in countries where ALK inhibitors are not approved or available. The protocol will further evaluate the safety of LDK378 in patients with ALK(+) NSCLC.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (28)
Ironwood Cancer and Research Centers
🇺🇸Chandler, Arizona, United States
Banner MDACC
🇺🇸Gilbert, Arizona, United States
Western Regional Medical Center, Inc.
🇺🇸Goodyear, Arizona, United States
Highlands Oncology Group
🇺🇸Fayetteville, Arkansas, United States
City of Hope National Medical Center
🇺🇸Duarte, California, United States
Moores UCSD Cancer Center
🇺🇸La Jolla, California, United States
St Joseph Heritage Healthcare
🇺🇸Santa Rosa, California, United States
Stanford University
🇺🇸Stanford, California, United States
Eastern Connecticut Hematology & Oncology Associates
🇺🇸Norwich, Connecticut, United States
Advanced Medical Specialties
🇺🇸Miami, Florida, United States
Scroll for more (18 remaining)Ironwood Cancer and Research Centers🇺🇸Chandler, Arizona, United States